| Project/Area Number |
25640077
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Tumor diagnostics
|
|---|
| Research Institution | Kyoto University |
|---|
Principal Investigator |
HASEGAWA Kouichi 京都大学, 物質-細胞統合システム拠点, 講師 (50378890)
|
|---|
| Research Collaborator |
PERA Martin F メルボルン大学, 教授
SARKAR Subhanwita インド国立幹細胞生物学再生医学研究センター(inStem), 研究員
|
|---|
| Project Period (FY) |
2013-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2014: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Fiscal Year 2013: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Keywords | 腫瘍診断 / 腫瘍マーカー / 抗体 / 膵癌 / 胆管癌 / 標的医療 |
|---|
| Outline of Final Research Achievements |
Pancreatic cancer has almost no symptoms and is difficult to diagnose in early phase. Therefore, the survival rate after 5 years of diagnosis is approximately 5% and worst among cancers. Although several pancreatic cancer markers, such as CA19-9, are used for diagnosis, the markers are less specific and difficult to use for early phase of the cancer. In previous study, we have developed novel pancreatic cancer marker GCTM-5 by utilizing similarity between pancreatic cancer and pancreatic progenitors differentiated from human pluripotent stem cells. However GCTM-5 also marks some of liver cancer. Therefore we challenged identification of components of GCTM-5 antigen complex in pancreatic and liver cancers, and development of more specific marker antibodies. Through this project, we have identified molecules specifically expressed in GCTM-5-positive pancreatic or liver cancer, and developed new antibodies recognize pancreatic cancer.
|
